DOCKET NO.: PH-7121-DIV1

USSN: 10/779,539

AMENDMENT

Subject matter to be added is in bold and underlined. Subject matter to be deleted is in bold and strikethrough.

In the Claims:

Please enter rewritten claims 1-7 and 10 and new claims 11-22 as follows. Please cancel claim 9 without prejudice.

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently amended) A compound of formula I:

I

or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;

A is selected from -COR⁵, -CO₂H, CH₂CO₂H, -CO₂R⁶, -CONHOH, -CONHOR⁵, -CONHOR⁶, -N(OH)COR⁵, -N(OH)CHO, -SH, -CH₂SH, -S(O)(=NH)R^a, -SN₂H₂R^a, -PO(OH)₂, and -PO(OH)NHR^a;

ring B is a 3-13 membered non-aromatic carbocyclic or heterocyclic ring comprising: earbon atoms, 0-3 carbonyl groups, 0-4 double bonds, and from 0-2 ring

DOCKET NO.: PH-7121-DIV1

USSN: 10/779,539

heteroatoms selected from O, N, NR^2 , and $S(O)_p$, provided that ring B contains other than a S-S, O-O, or S-O bond piperidinyl or pyridinyl;

Z is absent or selected from a C₃₋₁₃-carbocycle phenyl substituted with 0-4 R^b, naphthyl substituted with 0-5 R^b, and a 5-14 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and or tetrahydronaphthyl substituted with 0-5 R^b;

 U^a is absent or is selected from: O, NR^{a^l} , C(O), C(O)O, OC(O), C(O)NR $^{a^l}$, NR^{a^l} C(O), OC(O)O, OC(O)NR $^{a^l}$, NR^{a^l} C(O)O, NR^{a^l} C(O)O, NR^{a^l} C(O)NR $^{a^l}$, $S(O)_p$, $S(O)_pNR^{a^l}$, $NR^{a^l}S(O)_p$, and $NR^{a^l}SO_2NR^{a^l}$;

 X^a is absent or selected from C_{1-10} alkylene, C_{2-10} alkenylene, and C_{2-10} alkynylene;

Ya is absent or selected from O, NRa1, S(O)p, and C(O);

Z^a is selected from H, a C₃₋₁₃ carbocycle <u>pyridyl</u> substituted with 0-5 <u>0-4</u> R^c and a 5-14 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and <u>or quinolinyl</u> substituted with 0-5 R^c;

provided that Z, U^a, Y^a, and Z^a do not combine to form a N-N, N-O, O-N, O-O, S(O)_p-O, O-S(O)_p or S(O)_p-S(O)_p group;

 R^1 is selected from H, C_{1-4} alkyl, phenyl, and benzyl;

DOCKET NO.: PH-7121-DIV1

USSN: 10/779,539

 $R^{2} \text{ is selected from Q, Cl, F, C}_{1-10} \text{ alkylene-Q substituted with 0-3 R}^{b1}, C_{2-10} \text{ alkenylene-Q substituted with 0-3 R}^{b1}, C_{2-10} \text{ alkynylene-Q substituted with 0-3 R}^{b1}, \\ (CR^{a}R^{a^{1}})_{r^{1}}O(CR^{a}R^{a^{1}})_{r^{-}}Q, (CR^{a}R^{a^{1}})_{r^{1}}NR^{a}(CR^{a}R^{a^{1}})_{r^{-}}Q, (CR^{a}R^{a^{1}})_{r^{1}}C(O)(CR^{a}R^{a^{1}})_{r^{-}}Q, \\ (CR^{a}R^{a^{1}})_{r^{1}}C(O)O(CR^{a}R^{a^{1}})_{r^{-}}Q, (CR^{a}R^{a^{1}})_{r^{1}}C(O)O-C_{2-5} \text{ alkenylene, } (CR^{a}R^{a^{1}})_{r^{1}}C(O)O-C_{2-5} \text{ alkynylene, } (CR^{a}R^{a^{1}})_{r^{1}}OC(O)(CR^{a}R^{a^{1}})_{r^{-}}Q, (CR^{a}R^{a^{1}})_{r^{1}}C(O)NR^{a}R^{a^{1}}, \\ (CR^{a}R^{a^{1}})_{r^{1}}C(O)NR^{a}(CR^{a}R^{a^{1}})_{r^{-}}Q, (CR^{a}R^{a^{1}})_{r^{1}}NR^{a}C(O)(CR^{a}R^{a^{1}})_{r^{-}}Q, \\ (CR^{a}R^{a^{1}})_{r^{1}}OC(O)O(CR^{a}R^{a^{1}})_{r^{-}}Q, (CR^{a}R^{a^{1}})_{r^{1}}NR^{a}C(O)NR^{a}(CR^{a}R^{a^{1}})_{r^{-}}Q, \\ (CR^{a}R^{a^{1}})_{r^{1}}NR^{a}C(O)O(CR^{a}R^{a^{1}})_{r^{-}}Q, (CR^{a}R^{a^{1}})_{r^{1}}NR^{a}C(O)NR^{a}(CR^{a}R^{a^{1}})_{r^{-}}Q, \\ (CR^{a}R^{a^{1}})_{r^{1}}NR^{a}SO_{2}(CR^{a}R^{a^{1}})_{r^{-}}Q, (CR^{a}R^{a^{1}})_{r^{1}}NR^{a}SO_{2}NR^{a}(CR^{a}R^{a^{1}})_{r^{-}}Q; \\ (CR^{a}R^{a^{1}})_{r^{1}}NR^{a}SO_{2}(CR^{a}R^{a^{1}})_{r^{-}}Q, \text{ and } (CR^{a}R^{a^{1}})_{r^{1}}NR^{a}SO_{2}NR^{a}(CR^{a}R^{a^{1}})_{r^{-}}Q; \\ (CR^{a}R^{a^{1}})_{r^{1}}NR^{a}SO_{2}(CR^{a}R^{a^{1}})_{r^{1}}NR^{a}SO_{2}NR^{a}(CR^{a}R^{a^{1}})_{r^{1}}Q; \\ (CR^{a}R^{a^{1}})_{r^{1}}NR^{a}SO_{2}(CR^{a}R^{a^{1}})_{r^{1}}Q, \\ (CR^{a}R^{a^{1}})_{r^{1}}NR^{a}SO_{2}(CR^{a}R^{a^{1}})_{r^{1}}Q, \\ (CR^{a}R^{a^{1}})_{r^{1}}NR^{a}$

R^{2a} is selected from H, C₁₋₆ alkyl, OR^a, NR^aR^{a¹}, and S(O)_pR^a;

R^{2b} is H or C₁₋₆ alkyl;

- Q is selected from H, <u>and</u> a C₃₋₁₃ carbocycle substituted with 0-5 R^d and a 5-14 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and substituted with 0-5 R^d;
- $$\begin{split} R^3 \text{ is selected from } Q^1, & \text{Cl, F, C}_{1-6} \text{ alkylene-} Q^1, \text{C}_{2-6} \text{ alkenylene-} Q^1, \text{C}_{2-6} \text{ alkynylene-} Q^1, \\ & (\text{CR}^a\text{R}^a^l)_{r^l} \text{O}(\text{CR}^a\text{R}^a^l)_{r^-} Q^1, (\text{CR}^a\text{R}^a^l)_{r^l} \text{NR}^a (\text{CR}^a\text{R}^a^l)_{r^-} Q^1, \\ & (\text{CR}^a\text{R}^a^l)_{r^l} \text{NR}^a \text{C}(\text{O})(\text{CR}^a\text{R}^a^l)_{r^-} Q^1, (\text{CR}^a\text{R}^a^l)_{r^l} \text{C}(\text{O}) \text{NR}^a (\text{CR}^a\text{R}^a^l)_{r^-} Q^1, \\ & (\text{CR}^a\text{R}^a^l)_{r^l} \text{C}(\text{O})(\text{CR}^a\text{R}^a^l)_{r^-} Q^1, (\text{CR}^a\text{R}^a^l)_{r^l} \text{C}(\text{O}) \text{O}(\text{CR}^a\text{R}^a^l)_{r^-} Q^1, \\ & (\text{CR}^a\text{R}^a^l)_{r^l} \text{S}(\text{O})_p (\text{CR}^a\text{R}^a^l)_{r^-} Q^1, \text{ and } (\text{CR}^a\text{R}^a^l)_{r^l} \text{SO}_2 \text{NR}^a (\text{CR}^a\text{R}^a^l)_{r^-} Q^1; \end{split}$$
- Q¹ is selected from H, phenyl substituted with 0-3 R^d, <u>and</u> naphthyl substituted with 0-3 R^d
 and a 5-10 membered heteroaryl comprising: carbon atoms and 1-4

DOCKET NO.: PH-7121-DIV1

USSN: 10/779,539

heteroatoms selected from the group consisting of N, O, and $S(O)_p$ and substituted with 0-3 \mathbb{R}^d :

Ra, at each occurrence, is independently selected from H, C₁₋₄ alkyl, phenyl and benzyl;

 $R^{a^{l}}$, at each occurrence, is independently selected from H and C_{1-4} alkyl;

alternatively, R^a and R^{a¹} when attached to a nitrogen are taken together with the nitrogen to which they are attached to form a 5 or 6 membered ring comprising carbon atoms and from 0-1 additional heteroatoms selected from the group consisting of N, O, and S(O)_p;

 R^{a^2} , at each occurrence, is independently selected from C_{1-4} alkyl, phenyl and benzyl;

 R^b , at each occurrence, is independently selected from C_{1-6} alkyl, OR^a , Cl, F, Br, I, =O, -CN, NO_2 , $NR^aR^{a^1}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a^1}$, $R^aNC(O)NR^aR^{a^1}$, $OC(O)NR^aR^{a^1}$, $R^aNC(O)O$, $S(O)_2NR^aR^{a^1}$, $NR^aS(O)_2R^a^2$, $NR^aS(O)_2NR^aR^{a^1}$, $OS(O)_2NR^aR^{a^1}$, $NR^aS(O)_2R^{a^2}$, $S(O)_DR^{a^2}$

 $R^{b_1^1}$, at each occurrence, is independently selected from OR^a , Cl, F, Br, I, =0, -CN, NO_2 , and $NR^aR^{a_1^1}$;

R^c, at each occurrence, is independently selected from C₁₋₆ alkyl, OR^a, Cl, F, Br, I, =O, -CN, NO₂, NR^aR^{a¹}, C(O)R^a, C(O)OR^a, C(O)NR^aR^{a¹}, R^aNC(O)NR^aR^{a¹}, OC(O)NR^aR^{a¹}, RaNC(O)O, S(O)₂NR^aR^{a¹}, NRaS(O)₂Ra², NRaS(O)₂NRaRa¹, OS(O)₂NRaRa¹, NRaS(O)₂Ra², S(O)_pRa², CF₃, CF₂CF₃, and C₃₋₁₀ carbocycle substituted with 0-3 R^{c1} and a 5-14 membered heterocycle comprising: carbon atoms and 1-4

DOCKET NO.: PH-7121-DIV1

USSN: 10/779,539

heteroatoms selected from the group consisting of N, O, and $S(O)_p$ and substituted with 0-3 R^{el} :

- R^{c1}, at each occurrence, is independently selected from C₁₋₆ alkyl, OR^a, Cl, F, Br, I, =O,
 -CN, NO₂, NR^aR^{a¹}, C(O)R^a, C(O)OR^a, C(O)NR^aR^{a¹}, R^aNC(O)NR^aR^{a¹},
 OC(O)NR^aR^{a¹}, R^aNC(O)O, S(O)₂NR^aR^{a¹}, NR^aS(O)₂R^{a²}, NR^aS(O)₂NR^aR^{a¹},
 OS(O)₂NR^aR^{a¹}, NR^aS(O)₂R^{a²}, S(O)_pR^{a²}, CF₃, and CF₂CF₃;
- Rd, at each occurrence, is independently selected from C_{1-6} alkyl, OR^a , Cl, F, Br, I, =O, -CN, NO_2 , $NR^aR^a^l$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^a^l$, $R^aNC(O)NR^aR^a^l$, $OC(O)NR^aR^a^l$, $R^aNC(O)O$, $S(O)_2NR^aR^a^l$, $NR^aS(O)_2R^a^2$, $NR^aS(O)_2NR^aR^a^l$, $OS(O)_2NR^aR^a^l$, $NR^aS(O)_2R^a^2$, $S(O)_pR^a^2$, CF_3 , CF_2CF_3 , and C_{3-10} carbocycle and a 5-14 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$;
- R^5 , at each occurrence, is selected from C_{1-10} alkyl substituted with 0-2 R^b , and C_{1-8} alkyl substituted with 0-2 R^e ;
- R^e, at each occurrence, is selected from phenyl substituted with 0-2 R^b and biphenyl substituted with 0-2 R^b;
- R^6 , at each occurrence, is selected from phenyl, naphthyl, $C_{1\text{-}10}$ alkyl-phenyl- $C_{1\text{-}6}$ alkyl-, $C_{3\text{-}11}$ cycloalkyl, $C_{1\text{-}6}$ alkylcarbonyloxy- $C_{1\text{-}3}$ alkyl-, $C_{1\text{-}6}$ alkoxycarbonyloxy- $C_{1\text{-}3}$ alkyl-, $C_{2\text{-}10}$ alkoxycarbonyl, $C_{3\text{-}6}$ cycloalkylcarbonyloxy- $C_{1\text{-}3}$ alkyl-, $C_{3\text{-}6}$ cycloalkoxycarbonyl, phenoxycarbonyl, phenoxycarbonyl, phenyloxycarbonyloxy- $C_{1\text{-}3}$ alkyl-, phenylcarbonyloxy- $C_{1\text{-}3}$ alkyl-, $C_{1\text{-}6}$ alkoxy- $C_{1\text{-}6}$ alkoxy- $C_{1\text{-}6}$ alkylcarbonyloxy- $C_{1\text{-}3}$ alkyl-, $C_{1\text{-}6}$ alkyl-, $C_{1\text{-}6}$

DOCKET NO.: PH-7121-DIV1

USSN: 10/779,539

alkyl)-1,3-dioxa-cyclopenten-2-one-yl]methyl,

[5-(Ra)-1,3-dioxa-cyclopenten-2-one-yl]methyl,

 $(5\text{-}aryl\text{-}1,3\text{-}dioxa\text{-}cyclopenten\text{-}2\text{-}one\text{-}yl) methyl, \text{-}C_{1\text{-}10} \text{ alkyl\text{-}NR}^{7}R^{7a},$

-CH(R^8)OC(=O) R^9 , and -CH(R^8)OC(=O)OR 9 ;

 R^7 is selected from H and C_{1-10} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl- C_{1-3} alkyl-, and phenyl- C_{1-6} alkyl-;

 R^{7a} is selected from H and C_{1-10} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl- C_{1-3} alkyl-, and phenyl- C_{1-6} alkyl-;

 R^8 is selected from H and C_{1-4} linear alkyl;

 R^9 is selected from H, C_{1-8} alkyl substituted with 1-2 R^f , C_{3-8} cycloalkyl substituted with 1-2 R^f , and phenyl substituted with 0-2 R^b ;

 R^f , at each occurrence, is selected from C_{1-4} alkyl, C_{3-8} cycloalkyl, C_{1-5} alkoxy, and phenyl substituted with 0-2 R^b ;

p, at each occurrence, is selected from 0, 1, and 2;

r, at each occurrence, is selected from 0, 1, 2, 3, and 4; and,

 r^{1} , at each occurrence, is selected from 0, 1, 2, 3, and 4.

2. (Currently amended) A compound according to Claim 1, wherein the compound is of formula II:

DOCKET NO.: PH-7121-DIV1

USSN: 10/779,539

 Π

or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;

A is selected from -CO₂H, CH₂CO₂H, -CONHOH, -CONHOR⁵, -CONHOR⁶, -N(OH)COR⁵, -N(OH)CHO, -SH, and -CH₂SH;

- ring B is a 4-7 membered non-aromatic carbocyclic or heterocyclic ring comprising:
 carbon atoms, 0-1 carbonyl groups, 0-1 double bonds, and from 0-2 ring
 heteroatoms selected from O, N, and NR², provided that ring B contains other
 than a O-O bond piperidinyl or pyridinyl;
- Z is absent or selected from a C₃₋₁₁-carbocycle phenyl substituted with 0-4 R^b, naphthyl substituted with 0-4 R^b, and a 5-14 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and or tetrahydronaphthyl substituted with 0-4 0-3 R^b;

 U^a is absent or is selected from: O, NR^{a^1} , C(O), C(O)O, C(O) NR^{a^1} , NR^{a^1} C(O), S(O) $_p$, and $S(O)_pNR^{a^1}$;

 X^a is absent or selected from $C_{1\text{--}4}$ alkylene, $C_{2\text{--}4}$ alkenylene, and $C_{2\text{--}4}$ alkynylene;

Ya is absent or selected from O and NRa1;

DOCKET NO.: PH-7121-DIV1

USSN: 10/779,539

Za is selected from H, a C₃₋₁₀ carbocycle pyridyl substituted with 0-5 0-4 Rc and a 5-14 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and or quinolinyl substituted with 0-5 Rc;

provided that Z, Ua, Ya, and Za do not combine to form a N-N, N-O, O-N, O-O, $S(O)_p$ -O, $O-S(O)_p$ or $S(O)_p$ -S O_p group;

 R^1 is selected from H, C_{1-4} alkyl, phenyl, and benzyl;

$$\begin{split} R^2 \text{ is selected from } Q, C_{1\text{-}6} \text{ alkylene-} Q, C_{2\text{-}6} \text{ alkenylene-} Q, C_{2\text{-}6} \text{ alkynylene-} Q, \\ & (CR^aR^{a^l})_{r^l} O(CR^aR^{a^l})_{r^-} Q, (CR^aR^{a^l})_{r^l} NR^a (CR^aR^{a^l})_{r^-} Q, (CR^aR^{a^l})_{r^l} C(O)(CR^aR^{a^l})_{r^-} Q, \\ & (CR^aR^{a^l})_{r^l} C(O) O(CR^aR^{a^l})_{r^-} Q, (CR^aR^{a^l})_{r^-} C(O)NR^aR^{a^l}, \\ & (CR^aR^{a^l})_{r^l} C(O)NR^a (CR^aR^{a^l})_{r^-} Q, (CR^aR^{a^l})_{r^l} S(O)_p (CR^aR^{a^l})_{r^-} Q, \text{ and} \\ & (CR^aR^{a^l})_{r^l} SO_2NR^a (CR^aR^{a^l})_{r^-} Q; \end{split}$$

Q is selected from H, <u>and</u> a C₃₋₆ carbocycle substituted with 0-5 R^d, and a 5-10 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and substituted with 0-5 R^d;

Ra, at each occurrence, is independently selected from H, C₁₋₄ alkyl, phenyl and benzyl;

 $R^{a^{1}}$, at each occurrence, is independently selected from H and C_{1-4} alkyl;

alternatively, Ra and Ra when attached to a nitrogen are taken together with the nitrogen to which they are attached to form a 5 or 6 membered ring comprising carbon atoms and

DOCKET NO.: PH-7121-DIV1

USSN: 10/779,539

from 0-1 additional heteroatoms selected from the group consisting of N, O, and $S(O)_p$;

- Ra², at each occurrence, is independently selected from C₁₋₄ alkyl, phenyl and benzyl;
- R^b , at each occurrence, is independently selected from C_{1-6} alkyl, OR^a , Cl, F, Br, =0, -CN, $NR^aR^{a^l}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a^l}$, $S(O)_2NR^aR^{a^l}$, $S(O)_pR^{a^2}$, and CF_3 ;
- R^c, at each occurrence, is independently selected from C₁₋₆ alkyl, OR^a, Cl, F, Br, =O, -CN, NR^aR^{a¹}, C(O)R^a, C(O)OR^a, C(O)NR^aR^{a¹}, S(O)₂NR^aR^{a¹}, S(O)_pR^{a²}, CF₃, and C₃₋₆ carbocycle and a 5-6 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p;
- R^d , at each occurrence, is independently selected from C_{1-6} alkyl, OR^a , Cl, F, Br, =O, -CN, $NR^aR^{a^1}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a^1}$, $S(O)_2NR^aR^{a^1}$, $S(O)_pR^{a^2}$, CF_3 , and C_{3-6} carbocycle and a 5-6 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$;
- R^5 , at each occurrence, is selected from C_{1-6} alkyl substituted with 0-2 R^b , and C_{1-4} alkyl substituted with 0-2 R^e ;
- Re, at each occurrence, is selected from phenyl substituted with 0-2 Rb and biphenyl substituted with 0-2 Rb;
- R^6 , at each occurrence, is selected from phenyl, naphthyl, $C_{1\text{-}10}$ alkyl-phenyl- $C_{1\text{-}6}$ alkyl-, $C_{3\text{-}11}$ cycloalkyl, $C_{1\text{-}6}$ alkylcarbonyloxy- $C_{1\text{-}3}$ alkyl-, $C_{1\text{-}6}$ alkoxycarbonyloxy- $C_{1\text{-}3}$ alkyl-, $C_{2\text{-}10}$ alkoxycarbonyl, $C_{3\text{-}6}$ cycloalkylcarbonyloxy- $C_{1\text{-}3}$ alkyl-, $C_{3\text{-}6}$

DOCKET NO.: PH-7121-DIV1

Amendment

USSN: 10/779,539

- R^7 is selected from H and C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl- C_{1-3} alkyl-, and phenyl- C_{1-6} alkyl-;
- R^{7a} is selected from H and C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl- C_{1-3} alkyl-, and phenyl- C_{1-6} alkyl-;
- R^8 is selected from H and C_{1-4} linear alkyl;
- R^9 is selected from H, C_{1-6} alkyl substituted with 1-2 R^f , C_{3-6} cycloalkyl substituted with 1-2 R^f , and phenyl substituted with 0-2 R^b ;
- R^f , at each occurrence, is selected from C_{1-4} alkyl, C_{3-6} cycloalkyl, C_{1-5} alkoxy, and phenyl substituted with 0-2 R^b ;
- p, at each occurrence, is selected from 0, 1, and 2;
- r, at each occurrence, is selected from 0, 1, 2, 3, and 4; and,
- r¹, at each occurrence, is selected from 0, 1, 2, 3, and 4.

DOCKET NO.: PH-7121-DIV1

USSN: 10/779,539

3. (Currently amended) A compound according to Claim 2, wherein the compound is of formula IIIa or IIIb:

or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;

A is selected from -CO₂H, CH₂CO₂H, -CONHOH, -CONHOR⁵, -N(OH)CHO, and -N(OH)COR⁵;

Z is absent or selected from a C_{5-6} carbocycle phenyl substituted with 0-3 R^b and a 5-6 membered heteroaryl comprising carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$ and substituted with 0-3 R^b ;

Ua is absent or is selected from: O, NRa¹, C(O), C(O)NRa¹, S(O)_p, and S(O)_pNRa¹;

 X^a is absent or selected from C_{1-4} alkylene, C_{2-4} alkenylene, and C_{2-4} alkynylene

Ya is absent or selected from O and NRa1;

Z^a is selected from H, a C₅₋₆-carbocycle <u>pyridyl</u> substituted with 0-3 R^c and a 5-10 membered heteroaryl comprising carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and <u>or quinolinyl</u> substituted with 0-3 R^c;

DOCKET NO.: PH-7121-DIV1

USSN: 10/779,539

provided that Z, Ua, Ya, and Za do not combine to form a N-N, N-O, O-N, O-O, $S(O)_p$ -O, $O-S(O)_p$ or $S(O)_p$ -S O_p group;

R¹ is selected from H, C₁₋₄ alkyl, phenyl, and benzyl;

- $$\begin{split} R^2 \text{ is selected from Q, C$_{1-6}$ alkylene-Q, C$_{2-6}$ alkenylene-Q, C$_{2-6}$ alkynylene-Q,} \\ & (CR^aR^{a^l})_{r^l}C(O)(CR^aR^{a^l})_{r^-}Q, (CR^aR^{a^l})_{r^l}C(O)O(CR^aR^{a^l})_{r^-}Q, (CR^aR^{a^2})_{r^l}C(O)NR^aR^{a^l},} \\ & (CR^aR^a^2)_{r^l}C(O)NR^a(CR^aR^{a^l})_{r^-}Q, \text{ and } (CR^aR^{a^l})_{r^l}S(O)_p(CR^aR^{a^l})_{r^-}Q; \end{split}$$
- Q is selected from H, <u>and</u> a C₃₋₆ carbocycle substituted with 0-3 R^d and a 5-10 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and substituted with 0-3 R^d;

 R^{a} , at each occurrence, is independently selected from H, C_{1-4} alkyl, phenyl and benzyl;

 R^{a1} , at each occurrence, is independently selected from H and C_{1-4} alkyl;

Ra2, at each occurrence, is independently selected from C1-4 alkyl, phenyl, and benzyl;

- Rb, at each occurrence, is independently selected from C_{1-4} alkyl, OR^a , Cl, F, =0, $NR^aR^{a^1}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a^1}$, $S(O)_2NR^aR^{a^1}$, $S(O)_pR^{a^2}$, and CF_3 ;
- R^c , at each occurrence, is independently selected from C_{1-6} alkyl, OR^a , Cl, F, Br, =O, $NR^aR^{a^1}$, $C(O)R^a$, $C(O)NR^aR^{a^1}$, $S(O)_2NR^aR^{a^1}$, $S(O)_pR^{a^2}$, and CF_3 ;
- R^d , at each occurrence, is independently selected from C_{1-6} alkyl, OR^a , Cl, F, Br, =O, $NR^aR^{a^1}, C(O)R^a, C(O)NR^aR^{a^1}, S(O)_2NR^aR^{a^1}, S(O)_pR^{a^2}, CF_3, \text{ and phenyl};$

DOCKET NO.: PH-7121-DIV1

USSN: 10/779,539

 R^5 , at each occurrence, is selected from C_{1-4} alkyl substituted with 0-2 R^b , and C_{1-4} alkyl substituted with 0-2 R^e ;

Re, at each occurrence, is selected from phenyl substituted with 0-2 Rb and biphenyl substituted with 0-2 Rb;

p, at each occurrence, is selected from 0, 1, and 2;

r, at each occurrence, is selected from 0, 1, 2, 3, and 4;

r¹, at each occurrence, is selected from 0, 1, 2, 3, and 4; and,

s and s¹ combine to total 2, 3, or 4.

4. (Currently amended) A compound according to Claim 3, wherein the compound is of formula IVa or IVb:

or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein;

Z is absent or selected from phenyl substituted with 0-3 R^b and pyridyl substituted with 0-3 R^b;

Ua is absent or is O;

DOCKET NO.: PH-7121-DIV1

USSN: 10/779,539

Xa is absent or is CH2 or CH2CH2;

Ya is absent or is O;

Z^a is selected from H, phenyl substituted with 0-3 R^e, pyridyl substituted with 0-3 R^c, and or quinolinyl substituted with 0-3 R^c;

provided that Z, Ua, Ya, and Za do not combine to form a N-N, N-O, O-N, or O-O group;

 R^1 is selected from H, CH_3 , and CH_2CH_3 ;

$$\begin{split} R^2 \text{ is selected from Q, C$_{1-6}$ alkylene-Q, C$_{2-6}$ alkynylene-Q, C$_{O}(CR^aR^{a^l})_r$-Q, \\ C(O)O(CR^aR^{a^l})_r$-Q, C(O)NR^a(CR^aR^{a^l})_r$-Q, and S(O)_p(CR^aR^{a^l})_r$-Q; \end{split}$$

Q is selected from H, cyclopropyl substituted with 0-1 R^d, cyclobutyl substituted with 0-1 R^d, cyclopentyl substituted with 0-1 R^d, cyclohexyl substituted with 0-1 R^d, and phenyl substituted with 0-2 R^d and a heteroaryl substituted with 0-3 R^d, wherein the heteroaryl is selected from pyridyl, quinolinyl, thiazolyl, furanyl, imidazolyl, and isoxazolyl;

Ra, at each occurrence, is independently selected from H, CH3, and CH2CH3;

Ra¹, at each occurrence, is independently selected from H, CH₃, and CH₂CH₃;

Ra², at each occurrence, is independently selected from H, CH₃, and CH₂CH₃;

DOCKET NO.: PH-7121-DIV1

- R^b , at each occurrence, is independently selected from C_{1-4} alkyl, OR^a , Cl, F, =0, $NR^aR^{a^1}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a^1}$, $S(O)_2NR^aR^{a^1}$, $S(O)_pR^{a^2}$, and CF_3 ;
- R^c , at each occurrence, is independently selected from C_{1-6} alkyl, OR^a , Cl, F, Br, =O, $NR^aR^{a^1}$, $C(O)R^a$, $C(O)NR^aR^{a^1}$, $S(O)_2NR^aR^{a^1}$, $S(O)_pR^{a^2}$, and CF_3 ;
- R^d , at each occurrence, is independently selected from C_{1-6} alkyl, OR^a , Cl, F, Br, =O, $NR^aR^{a^1}$, $C(O)R^a$, $C(O)NR^aR^{a^1}$, $S(O)_2NR^aR^{a^1}$, $S(O)_pR^{a^2}$, CF_3 and phenyl;
- p, at each occurrence, is selected from 0, 1, and 2;
- r, at each occurrence, is selected from 0, 1, 2, and 3;
- r¹, at each occurrence, is selected from 0, 1, 2, and 3; and,
- s and s¹ combine to total 2, 3, or 4.
- 5. (Currently amended) A compound according to Claim 2, wherein;
- A is selected from -CO₂H, CH₂CO₂H, -CONHOH, -CONHOR⁵, -N(OH)CHO, and -N(OH)COR⁵;
- ring B is a 4-7 membered non-aromatic carbocyclic or heterocyclic ring comprising:
 carbon atoms, 0-1 carbonyl groups, 0-1 double bonds, and from 0-2 ring
 heteroatoms selected from O, N, and NR², provided that ring B contains other
 than a O-O bond piperidinyl or pyridinyl;

DOCKET NO.: PH-7121-DIV1

USSN: 10/779,539

Z is absent or selected from a C_{5-6} -carbocycle phenyl substituted with 0-3 R^b and a 5-6 membered heteroaryl comprising earbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and $S(O)_p$ and substituted with 0-3 R^b ;

 U^a is absent or is selected from: O, NR^{a^1} , C(O), C(O) NR^{a^1} , S(O)_p, and S(O)_p NR^{a^1} ;

 X^a is absent or selected from C_{1-2} alkylene, C_{2-4} alkenylene, and C_{2-4} alkynylene

Ya is absent or selected from O and NRa1;

Z^a is selected from H, a-C₅₋₆ carbocycle <u>pyridyl</u> substituted with 0-3 R^c and a 5-10 membered heteroaryl comprising carbon atoms and from 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_p and or quinolinyl substituted with 0-3 R^c;

provided that Z, Ua, Ya, and Za do not combine to form a N-N, N-O, O-N, O-O, $S(O)_p$ -O, $O-S(O)_p$ or $S(O)_p$ -S $O)_p$ group;

 R^1 is selected from H, C_{1-4} alkyl, phenyl, and benzyl;

 $R^2 \text{ is } (CR^aR^{a^1})_{r^1}O(CR^aR^{a^1})_{r^2}Q \text{ or } (CR^aR^{a^1})_{r^1}NR^a(CR^aR^{a^1})_{r^2}Q;$

Q is selected from H, <u>and</u> a C₃₋₆ carbocycle substituted with 0-3 R^d and a 5-10 membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from the group consisting of N, O, and S(O)_D and substituted with 0-3 R^d;

DOCKET NO.: PH-7121-DIV1

USSN: 10/779,539

Ra, at each occurrence, is independently selected from H, C₁₋₄ alkyl, phenyl and benzyl;

 R^{a^1} , at each occurrence, is independently selected from H and C_{1-4} alkyl;

Ra2, at each occurrence, is independently selected from C1-4 alkyl, phenyl and benzyl;

 R^b , at each occurrence, is independently selected from C_{1-4} alkyl, OR^a , Cl, F, =0, $NR^aR^{a^1}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a^1}$, $S(O)_2NR^aR^{a^1}$, $S(O)_pR^{a^2}$, and CF_3 ;

 R^c , at each occurrence, is independently selected from C_{1-6} alkyl, OR^a , Cl, F, Br, =O, $NR^aR^{a^1}$, $C(O)R^a$, $C(O)NR^aR^{a^1}$, $S(O)_2NR^aR^{a^1}$, $S(O)_pR^{a^2}$, and CF_3 ;

 R^d , at each occurrence, is independently selected from C_{1-6} alkyl, OR^a , Cl, F, Br, =O, $NR^aR^{a^1}$, $C(O)R^a$, $C(O)NR^aR^{a^1}$, $S(O)_2NR^aR^{a^1}$, $S(O)_pR^{a^2}$, CF_3 and phenyl;

 R^5 , at each occurrence, is selected from C_{1-4} alkyl substituted with 0-2 R^b , and C_{1-4} alkyl substituted with 0-2 R^e ;

Re, at each occurrence, is selected from phenyl substituted with 0-2 Rb and biphenyl substituted with 0-2 Rb;

p, at each occurrence, is selected from 0, 1, and 2;

r, at each occurrence, is selected from 0, 1, 2, 3, and 4; and,

r¹, at each occurrence, is selected from 0, 1, 2, 3, and 4.

DOCKET NO.: PH-7121-DIV1

USSN: 10/779,539

6. (Currently amended) A compound according to Claim 5, wherein;

A is -CONHOH;

ring B is a 5-6 membered non-aromatic carbocyclic or heterocyclic ring comprising:

carbon atoms, 0-1 carbonyl groups, 0-1 double bonds, and from 0-2 ring

heteroatoms selected from O, N, and NR², provided that ring B contains other
than a O-O bond piperidinyl or pyridinyl;

Z is absent or selected from phenyl substituted with 0-3 R^b and pyridyl substituted with 0-3 R^b;

Ua is absent or is O;

X^a is absent or is CH₂ or CH₂CH₂;

Ya is absent or is O;

Z^a is selected from H, phenyl substituted with 0-3 R^c, pyridyl substituted with 0-3 R^c, and or quinolinyl substituted with 0-3 R^c;

provided that Z, Ua, Ya, and Za do not combine to form a N-N, N-O, O-N, or O-O group;

 R^1 is selected from H, CH_3 , and CH_2CH_3 ;

 R^{2} is $(CR^{a}R^{a^{1}})_{r^{1}}O(CR^{a}R^{a^{1}})_{r^{-}}Q$ or $(CR^{a}R^{a^{1}})_{r^{1}}NR^{a}(CR^{a}R^{a^{1}})_{r^{-}}Q$;

DOCKET NO.: PH-7121-DIV1

USSN: 10/779,539

Q is selected from H, cyclopropyl substituted with 0-1 R^d, cyclobutyl substituted with 0-1 R^d, cyclopentyl substituted with 0-1 R^d, cyclohexyl substituted with 0-1 R^d, and phenyl substituted with 0-2 R^d, and a heteroaryl substituted with 0-3 R^d, wherein the heteroaryl is selected from pyridyl, quinolinyl, thiazolyl, furanyl, imidazolyl, and isoxazolyl;

Ra, at each occurrence, is independently selected from H, CH3, and CH2CH3;

Ra¹, at each occurrence, is independently selected from H, CH₃, and CH₂CH₃;

Ra2, at each occurrence, is independently selected from H, CH3, and CH2CH3;

 R^b , at each occurrence, is independently selected from C_{1-4} alkyl, OR^a , Cl, F, =0, $NR^aR^{a^1}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^aR^{a^1}$, $S(O)_2NR^aR^{a^1}$, $S(O)_pR^{a^2}$, and CF_3 ;

 R^c , at each occurrence, is independently selected from C_{1-6} alkyl, OR^a , Cl, F, Br, =O, $NR^aR^{a^1}$, $C(O)R^a$, $C(O)NR^aR^{a^1}$, $S(O)_2NR^aR^{a^1}$, $S(O)_pR^{a^2}$, and CF_3 ;

 R^d , at each occurrence, is independently selected from C_{1-6} alkyl, OR^a , Cl, F, Br, =O, $NR^aR^{a^1}$, $C(O)R^a$, $C(O)NR^aR^{a^1}$, $S(O)_2NR^aR^{a^1}$, $S(O)_pR^{a^2}$, CF_3 and phenyl;

p, at each occurrence, is selected from 0, 1, and 2;

r, at each occurrence, is selected from 0, 1, 2, and 3; and,

r¹, at each occurrence, is selected from 0, 1, 2, and 3.

DOCKET NO.: PH-7121-DIV1

USSN: 10/779,539

7. (Currently amended) A compound according to Claim 1, wherein the compound is selected from the group:

- $N-\{(1R,2S)-2-[(hydroxyamino)carbonyl]cyclopentyl\}-2'-(trifluoromethyl)[1,1'-biphenyl]-4-carboxamide$
- $N-\{(1R,2S)-2-[(hydroxyamino)carbonyl]cyclopentyl\}-4-[2-(trifluoromethyl)phenoxy]benzamide$
- $N-\{(1R,2S)-2-[(hydroxyamino)carbonyl]cyclopentyl\}-4-(3-methyl-2-pyridinyl)benzamide$

 $N-\{(1R,2S)-2-[(\text{hydroxyamino})\text{carbonyl}]\text{cyclopentyl}\}[1,1'-\text{biphenyl}]-4-\text{carboxamide}$ $N-\{(1R,2S)-2-[(\text{hydroxyamino})\text{carbonyl}]\text{cyclopentyl}\}-4-\text{phenoxybenzamide}$ $4-(\text{benzyloxy})-N-\{(1R,2S)-2-[(\text{hydroxyamino})\text{carbonyl}]\text{cyclopentyl}\}\text{benzamide}$ $N-\{(1R,2S)-2-[(\text{hydroxyamino})\text{carbonyl}]\text{cyclopentyl}\}-2'-\text{methoxy}[1,1'-\text{biphenyl}]-4-\text{carboxamide}$

 $N-\{(1R,2S)-2-[(hydroxyamino)carbonyl]eyelopentyl\}-2'-methyl[1,1'-biphenyl]-4-carboxamide$

 $N-\{(1R,2S)-2-[(\text{hydroxyamino})\text{carbonyl}]\text{cyclopentyl}\}-4-(2-\text{methoxyphenoxy})\text{benzamide}$ $N-\{(1R,2S)-2-[(\text{hydroxyamino})\text{carbonyl}]\text{cyclopentyl}\}-4-(2-\text{methylphenoxy})\text{benzamide}$ $N-\{(1R,2S)-2-[(\text{hydroxyamino})\text{carbonyl}]\text{cyclopentyl}\}-4-(3-\text{methylphenoxy})\text{benzamide}$

DOCKET NO.: PH-7121-DIV1

USSN: 10/779,539

4-(5,8-dihydro-4-quinolinyl)-N-{(1R,2S)-2-[(hydroxyamino)carbonyl]cyclopentyl}benzamide

N-{(1*R*,2*S*)-2-[(hydroxyamino)carbonyl]cyclopentyl}-3',5'-dimethyl[1,1'-biphenyl]-4-carboxamide

 $N-\{(1R,2S)-2-[(hydroxyamino)carbonyl] eyelopentyl\}-6-(2-methylphenyl) nicotina mide$

 $N-\{(1R,2S)-2-[(hydroxyamino)carbonyl]cyclopentyl\}-6-(2-methoxyphenyl)nicotinamide$

(3S,4S)-N-hydroxy-1-isopropyl-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide

- (3S,4S)-1-(2,2-dimethylpropanoyl)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy|benzoyl}amino)-3-pyrrolidinecarboxamide
- $\frac{(3S,4S)-N-hydroxy-4-(\{4-\{(2-methyl-4-quinolinyl)methoxy\}benzoyl\}amino)-1-(methylsulfonyl)-3-pyrrolidinecarboxamide}{}$
- $\frac{(3S,4S)-N-hydroxy-1-methyl-4-(\{4-[(2-methyl-4-quinolinyl)methoxy]benzoyl\}amino)-3-pyrrolidinecarboxamide}{}$
- (3S,4S)-N-hydroxy-4-([4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3pyrrolidinecarboxamide

DOCKET NO.: PH-7121-DIV1

- $\label{lem:carbonyl} \begin{tabular}{ll} $tert$-butyl $4-[cis-3-[(hydroxyamino)carbonyl]-4-(\{4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino)pyrrolidinyl]-1-piperidinecarboxylate \\ \end{tabular}$
- eis-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-(4-piperidinyl)-3-pyrrolidinecarboxamide
- $\label{eq:cis-1-[3-[(1,1-dimethylethoxy)carbonyl]pyrollidinyl]-N-hydroxy-3-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-pyrollidinecarboxamide} \\$
- cis-N-hydroxy-1-[3-pyrollidinyl]-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-pyrollidinecarboxamide
- $\frac{tert\text{-butyl} \ (3R,4R)\text{-}3\text{-}[(hydroxyamino)carbonyl]\text{-}4\text{-}(\{4\text{-}[(2\text{-methyl-}4\text{-}quinolinyl)methoxy}]benzoyl]amino)\text{-}1\text{-}pyrrolidinecarboxylate}$
- tert-butyl (3S,4R)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- (3S,4R)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3pyrrolidinecarboxamide
- tert-butyl (3R,4S)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- (3R,4S)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3pyrrolidinecarboxamide
- N {(1R,2S) 2 [(hydroxyamino)carbonyl]cyclopentyl} 4 (4-pyridinyl)benzamide

DOCKET NO.: PH-7121-DIV1

- (3S,4S)-1-(1,1-dimethyl-2-propynyl)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- $\frac{(3S,4S)-N-hydroxy-4-(\{4-[(2-methyl-4-quinolinyl)methoxy]benzoyl\}amino)-1-(2-methyl-3-pyrrolidinecarboxamide}{propynyl}$
- (3S,4S)-1-allyl-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- (3S,4S)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-propyl-3-pyrrolidinecarboxamide
- (3S,4S)-N-hydroxy-1-(2-methyl-2-propenyl)-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- $(3S,4S)-1-(1,1-dimethyl-2-propenyl)-N-hydroxy-4-(\{4-\{(2-methyl-4-quinolinyl)methoxy\}benzoyl\}amino)-3-pyrrolidinecarboxamide$
- (3S,4S)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-tert-pentyl-3-pyrrolidinecarboxamide
- (3S,4S)-N-hydroxy-1-isopentyl-4-([4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- (3S,4S)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-neopentyl-3-pyrrolidinecarboxamide
- (3S,4S)-1-butyl-N-hydroxy-4-([4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide

DOCKET NO.: PH-7121-DIV1

- $\frac{(3S,4S)-1-(3-butenyl)-N-hydroxy-4-(\{4-[(2-methyl-4-quinolinyl)methoxy]benzoyl\}amino)-3-pyrrolidinecarboxamide}{(3S,4S)-1-(3-butenyl)-N-hydroxy-4-(\{4-[(2-methyl-4-quinolinyl)methoxy]benzoyl\}amino)-3-pyrrolidinecarboxamide}{(3S,4S)-1-(3-butenyl)-N-hydroxy-4-(\{4-[(2-methyl-4-quinolinyl)methoxy]benzoyl\}amino)-3-pyrrolidinecarboxamide}{(3S,4S)-1-(3-butenyl)-N-hydroxy-4-(\{4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino)-3-pyrrolidinecarboxamide}{(3S,4S)-1-(3-butenyl)-N-hydroxy-4-(\{4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino)-3-pyrrolidinecarboxamide}{(3S,4S)-1-(3-butenyl)-N-hydroxy-4-(\{4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino)-3-pyrrolidinecarboxamide}{(3S,4S)-1-(3-butenyl)methoxy}{(3S,4S)-1-(3-butenyl)methox}{(3S,4S)-1-(3-butenyl)m$
- (3S,4S)-1-(2-butynyl)-N-hydroxy-4-([4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino)-3-pyrrolidinecarboxamide
- $\frac{(3S,4S)-1-(2-furylmethyl)-N-hydroxy-4-(\{4-[(2-methyl-4-quinolinyl)methoxy]benzoyl\}amino)-3-pyrrolidinecarboxamide}{(3S,4S)-1-(2-furylmethyl)-N-hydroxy-4-(\{4-[(2-methyl-4-$
- $\frac{(3S,4S)-N-hydroxy-1-[(5-methyl-2-furyl)methyl]-4-(\{4-[(2-methyl-4-quinolinyl)methoxy]benzoyl\}amino)-3-pyrrolidinecarboxamide}{(3S,4S)-N-hydroxy-1-[(5-methyl-2-furyl)methyl]-4-(\{4-[(2-methyl-4-methyl-4-(3S,4S)-N-hydroxy-1-[(5-methyl-2-furyl)methyl]-4-(\{4-[(2-methyl-4-methyl-4-(3S,4S)-N-hydroxy-1-[(5-methyl-2-furyl)methyl]-4-(\{4-[(2-methyl-4-methyl-4-(3S,4S)-N-hydroxy-1-[(5-methyl-2-furyl)methyl]-4-(\{4-[(2-methyl-4-methyl-4-(3S,4S)-N-hydroxy-1-[(5-methyl-2-furyl)methyl]-4-(\{4-[(2-methyl-4-methyl-4-(3S,4S)-N-hydroxy-1-[(5-methyl-4-(3S,4S)-n-hydroxy-1-[(5$
- (3R,4S)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)tetrahydro-3-furancarboxamide
- $\frac{(3S,4R)-N-hydroxy-4-(\{4-[(2-methyl-4-quinolinyl)methoxy]benzoyl\}amino)tetrahydro-3-furancarboxamide}{3-furancarboxamide}$
- $(3S,4S)-N-hydroxy-4-(\{4-[(2-methyl-4-quinolinyl)methoxy]benzoyl\}amino)-1-(1,3-thiazol-2-ylmethyl)-3-pyrrolidinecarboxamide$
- (3S,4S)-1-acetyl-N-hydroxy-4- $({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide$
- $(3S, 4S)-N-hydroxy-1-isobutyryl-4-(\{4-[(2-methyl-4-quinolinyl)methoxy]benzoyl\}amino)-3-pyrrolidinecarboxamide$

DOCKET NO.: PH-7121-DIV1

- (3S,4S)-N-hydroxy-1-(3-methylbutanoyl)-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- (3S,4S)-1-(cyclopropylcarbonyl)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- (3S,4S)-1-(cyclobutylcarbonyl)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy|benzoyl}amino)-3-pyrrolidinecarboxamide
- (3S,4S)-N-hydroxy-1-(methoxyacetyl)-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-3-pyrrolidinecarboxamide
- $\frac{(3S,4S)-1-(2-furoyl)-N-hydroxy-4-(\{4-[(2-methyl-4-quinolinyl)methoxy]benzoyl\}amino)-}{3-pyrrolidinecarboxamide}$
- (3S,4S)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-(2-thienylcarbonyl)-3-pyrrolidinecarboxamide
- (3S,4S)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-propionyl-3-pyrrolidinecarboxamide
- (3R,4S)-4-{[4-(2-butynyloxy)benzoyl]amino}-N-hydroxy-tetrahydro-3-furancarboxamide
- N-{(1R,2S)-2-[(hydroxyamino)carbonyl]-4-oxocyclopentyl}-4-[(2-methyl-4-quinolinyl)methoxy]benzamide
- $N-\{(1R,2S,4R)-4-\text{hydroxy-}2-[(\text{hydroxyamino})\text{carbonyl}]\text{cyclopentyl}\}-4-[(2-\text{methyl-}4-\text{guinolinyl})\text{methoxy}]\text{benzamide}$

DOCKET NO.: PH-7121-DIV1

USSN: 10/779,539

 $N-\{(1R,2S,4S)-4-hydroxy-2-[(hydroxyamino)carbonyl]cyclopentyl\}-4-[(2-methyl-4-quinolinyl)methoxy]benzamide$

- (3S,4S)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-tetrahydro-2H-pyran-4-yl-3-pyrrolidinecarboxamide
- $\frac{\text{methyl } (3S,4S)-3-[(hydroxyamino)carbonyl]-4-(\{4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino)-1-pyrrolidinecarboxylate}{}$
- ethyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- propyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- $\frac{\text{allyl } (3S,\!4S)\text{-}3\text{-}[(\text{hydroxyamino})\text{carbonyl}]\text{-}4\text{-}(\{4\text{-}[(2\text{-methyl}\text{-}4\text{-}(\text{uinolinyl})\text{methoxy}]\text{benzoyl}\}\text{amino})\text{-}1\text{-}pyrrolidinecarboxylate}}{\text{allyl } (3S,\!4S)\text{-}3\text{-}[(\text{hydroxyamino})\text{carbonyl}]\text{-}4\text{-}(\{4\text{-}[(2\text{-methyl}\text{-}4\text{-}(\text{uinolinyl})\text{methoxy}]\text{benzoyl}\}\text{amino})\text{-}1\text{-}pyrrolidinecarboxylate}}$
- isopropyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate
- $\begin{array}{lll} \textbf{2-propynyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-(\{4-[(2-methyl-4-quinolinyl)methoxy]benzoyl\}amino)-1-pyrrolidinecarboxylate} \end{array} \\$
- $\begin{array}{lll} \textbf{2-butynyl (3S,4S)-3-[(hydroxyamino)carbonyl]-4-(\{4-[(2-methyl-4-quinolinyl)methoxy]benzoyl\}amino)-1-pyrrolidinecarboxylate} \end{array}$

DOCKET NO.: PH-7121-DIV1

- ${\bf 3-butenyl~(3S,4S)-3-[(hydroxyamino)carbonyl]-4-(\{4-[(2-methyl-4-quinolinyl)methoxy]benzoyl\}amino)-1-pyrrolidinecarboxylate}$
- $\frac{benzyl\ (3S,4S)-3-[(hydroxyamino)carbonyl]-4-(\{4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino)-1-pyrrolidinecarboxylate}{}$
- $N-\{(1R,2S)-4-(dimethylamino)-2-[(hydroxyamino)carbonyl]cyclopentyl\}-4-[(2-methyl-4-quinolinyl)methoxy]benzamide$
- (3S,4S)-4-{[4-(2-butynyloxy)benzoyl]amino}-N-hydroxy-1-isopropyl-3pyrrolidinecarboxamide
- $N-\{(1R,2S)-4,4-difluoro-2-[(hydroxyamino)carbonyl]cyclopentyl\}-4-[(2-methyl-4-quinolinyl)methoxy]benzamide$
- (3S,4S)-N-hydroxy-1-isopropyl-4-{[4-(2-methylphenoxy)benzoyl]amino}-3-pyrrolidinecarboxamide
- cis-N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-cyclopentanecarboxamide
- trans-N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-cyclopentanecarboxamide
- $\frac{(1S,2R)-N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-cyclopentanecarboxamide}{cyclopentanecarboxamide}$
- $\frac{(1R,2S)-N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-cvclopentanecarboxamide}{}$

DOCKET NO.: PH-7121-DIV1

- eis-N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1eyclohexanecarboxamide
- trans-N-hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-cyclohexanecarboxamide
- trans-1-[[(1,1-dimethylethyl)oxy]carbonyl]-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-pyrrolidinecarboxamide
- trans-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-pyrrolidinecarboxamide
- $\label{lem:cis-1-[[(1,1-dimethylethyl)oxy]carbonyl]-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-pyrrolidinecarboxamide} \\$
- cis-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-pyrrolidinecarboxamide
- (3S,4R)-1-[[(1,1-dimethylethyl)oxy]carbonyl]-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- (3S,4S)-1-[[(1,1-dimethylethyl)oxy]carbonyl]-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- (3S,4S)-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide

DOCKET NO.: PH-7121-DIV1

- (3S,4R)-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- (3S,4R)-1-[(butoxy)carbonyl]-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- (3S,4R)-N-hydroxy-1-[[(1-methylethyl)oxy]carbonyl]-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- (3S,4R)-N-hydroxy-1-(methylsulfonyl)-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- (3S,4R)-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(phenylsulfonyl)-3-piperidinecarboxamide
- (3S,4R)-1-acetyl-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- (3S,4R)-1-benzoyl-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- (3S,4R)-1-(2,2-dimethylpripionyl)-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- (3S,4R)-1-(3,3-dimethylbutanoyl)-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- (3S,4R)-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(4-morpholinecarbonyl)-3-piperidinecarboxamide

DOCKET NO.: PH-7121-DIV1

- (3S,4R)-1-(dimethylcarbamyl)-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- (3S,4R)-N-hydroxy-1-methyl-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- (3S,4R)-1-ethyl-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- (3S,4R)-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-propyl-3-piperidinecarboxamide
- (3S,4R)-N-hydroxy-1-(1-methylethyl)-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- (3S,4R)-1-(cyclopropylmethyl)-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- (3S,4R)-1-(2,2-dimethylpropyl)-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- (3S,4R)-1-benzyl-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- (3S,4R)-1-(2-thiazolylmethyl)-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide

DOCKET NO.: PH-7121-DIV1

- (3S,4S)-1-[[(1,1-dimethylethyl)oxy]carbonyl]-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3R,4S)-1-[[(1,1-dimethylethyl)oxy]carbonyl]-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3R,4S)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-N-hydroxy-1-[[(2-methylpropyl)oxy]carbonyl]-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-N-hydroxy-1-(methoxycarbonyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-N-hydroxy-1-[(1-methylethoxy)carbonyl]-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-N-hydroxy-1-(methylsulfonyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(phenylsulfonyl)-4-piperidinecarboxamide
- (3S,4S)-1-(3,3-dimethylbutanoyl)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

DOCKET NO.: PH-7121-DIV1

- (3S,4S)-1-(2,2-dimethylpropionyl)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-1-benzoyl-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-1-[(pyridin-3-yl)carbonyl]-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(2-thiophenecarbonyl)-4-piperidinecarboxamide
- (3S,4S)-1-(dimethylcarbamyl)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(4-morpholinecarbonyl)-4-piperidinecarboxamide
- (3S,4S)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-[[2-(2-thienyl)ethyl]carbamyl]-4-piperidinecarboxamide
- (3S,4S)-1-[(1,1-dimethylethyl)carbamyl]-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-N-hydroxy-1-methyl-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

DOCKET NO.: PH-7121-DIV1

- (3S,4S)-1-ethyl-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-propyl-4-piperidinecarboxamide
- (3S,4S)-N-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-1-cyclobutyl-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-1-butyl-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(2-methylpropyl)-4-piperidinecarboxamide
- (3S,4S)-1-(cyclopropylmethyl)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-1-(2,2-dimethylpropyl)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-1-cyclopentyl-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(4-tetrahydropyranyl)-4-piperidinecarboxamide

DOCKET NO.: PH-7121-DIV1

- (3S,4S)-1-benzyl-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(2-thiazolylmethyl)-4-piperidinecarboxamide
- (3S,4S)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(4-pyridinylmethyl)-4-piperidinecarboxamide
- (3S,4S)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(2-pyridinylmethyl)-4-piperidinecarboxamide
- (3S,4S)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(3-pyridinylmethyl)-4-piperidinecarboxamide
- (3S,4S)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(trans-3-phenyl-2-propenyl)-4-piperidinecarboxamide
- (3S,4S)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-phenyl-4-piperidinecarboxamide
- (3R,4S)-1-(2,2-dimethylpropionyl)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3R,4S)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-methyl-4-piperidinecarboxamide

DOCKET NO.: PH-7121-DIV1

- (3R,4S)-1-(dimethylcarbamyl)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-1-hexyl-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-1-(2-fluoroethyl)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-1-(2,2-difluoroethyl)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-N-hydroxy-1-(1-methylpropyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-1-(1-ethylpropyl)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-1-[1-[[(1,1-dimethylethyl)oxy]carbonyl]-4-tetrahydropiperidinyl]-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(4-tetrahydropiperidinyl)-4-piperidinecarboxamide
- $(3S,4S)-1-[1-[[(1,1-\mathrm{dimethylethyl})\mathrm{oxy}]\mathrm{carbonyl}]-3-\mathrm{tetrahydropyrrolidinyl}]-N-\mathrm{hydroxy-3-}[[4-\mathrm{carbonyl}]\mathrm{-d-piperidine}]-4-\mathrm{piperidine}]$
- (3S,4S)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(3-tetrahydropyrrolidinyl)-4-piperidinecarboxamide

DOCKET NO.: PH-7121-DIV1

- (3S,4S)-1-(1,1-dimethyl-2-propynyl)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3*S*,4*S*)-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(3-thiophenylmethyl)-4-piperidinecarboxamide
- (3S,4S)-N-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-oxo-4-piperidinecarboxamide
- (3S,4S)-N-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-1-oxo-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-N-hydroxy-1-(1-methylethyl)-3-[[[4-[(2-methyl-1-oxo-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-oxo-4-piperidinecarboxamide
- (3S,4S)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-[2-(4-morpholinyl)-2-oxoethyl]-4-piperidinecarboxamide
- (3S,4S)-1-[2-(N,N-dimethylamino)-2-oxoethyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-1-(t-butylsulfonyl)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-1-(t-butylsulfonyl)-N-hydroxy-3-[[[4-[(2-methyl-1-oxo-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide

DOCKET NO.: PH-7121-DIV1

- (3S,4S)-1-(benzenesulfonyl)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-1-(t-butylsulfinyl)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-N-hydroxy-1-(2-hydroxylethyl)-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-1-[2-[[[(1,1-dimethylethyl)oxy]carbonyl]amino]ethyl]-*N*-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-1-(2-aminoethyl)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-1-[2-(N,N-dimethylamino)ethyl]-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-1-[(2S)-2-aminopropyl]-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-1-[(2R)-2-amino-3-hydroxypropyl]-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-4-piperidinecarboxamide
- (3S,4S)-N-hydroxy-3-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-[[(2R)-2-pyrrolidinyl]methyl]-4-piperidinecarboxamide
- (3S,4R)-N-hydroxy-1-(2-hydroxylethyl)-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide

DOCKET NO.: PH-7121-DIV1

- (3S,4R)-1-(2-aminoethyl)-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- (3S,4R)-1-cyclobutyl-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-3-piperidinecarboxamide
- (3R,4R)-N-hydroxy-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)tetrahydro-2H-pyran-3-carboxamide
- (3S,4S)-1-tert-butyl-N-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-4-piperidinecarboxamide
- tert-butyl 2-[(3S,4S)-4-[(hydroxyamino)carbonyl]-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)piperidinyl]-2-methylpropanoate
- 2-[(3S,4S)-4-[(hydroxyamino)carbonyl]-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)piperidinyl]-2-methylpropanoic acid
- methyl 2-[(3S,4S)-4-[(hydroxyamino)carbonyl]-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)piperidinyl]-2-methylpropanoate
- (3S,4S)-N-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-[2-(4-morpholinyl)-2-oxoethyl]-4-piperidinecarboxamide
- (3S,4S)-1-[2-(dimethylamino)-2-oxoethyl]-N-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-4-piperidinecarboxamide

DOCKET NO.: PH-7121-DIV1

- (3S,4S)-1-(1,1-dimethyl-2-propenyl)-N-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-4-piperidinecarboxamide
- (3*S*,4*S*)-*N*-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-*tert*-pentyl-4-piperidinecarboxamide
- (3S,4S)-N-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-(2-propynyl)-4-piperidinecarboxamide
- (3S,4S)-1-allyl-N-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-4-piperidinecarboxamide
- (3S,4S)-N-hydroxy-1-(1-methyl-2-propynyl)-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-4-piperidinecarboxamide
- (3S,4S)-N-hydroxy-1-(1-methyl-2-propenyl)-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-4-piperidinecarboxamide
- $N-\{(1R,2S)-4,5-dihydroxy-2-[(hydroxyamino)carbonyl]cyclohexyl\}-4-[(2-methyl-4-quinolinyl)methoxy]benzamide$
- (5S)-N-hydroxy-5-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-2-oxo-4-piperidinecarboxamide
- (3S,4S)-N-hydroxy-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-2-oxo-4-piperidinecarboxamide
- (3S,4S)-3-{[4-(2-butynyloxy)benzoyl]amino}-N-hydroxy-1-isopropyl-4piperidinecarboxamide

DOCKET NO.: PH-7121-DIV1

USSN: 10/779,539

$(3S,4S)-3-\{[4-(2-butynyloxy)benzoyl]amino\}-N-hydroxy-4-piperidine carboxamide$

- tert-butyl (3S,4S)-4-[(hydroxyamino)carbonyl]-3-({4-[(2-methyl-3-pyridinyl)methoxy]benzoyl}amino)-1-piperidinecarboxylate
- (3S,4S)-N-hydroxy-3-({4-[(2-methyl-3-pyridinyl)methoxy]benzoyl}amino)-4-piperidinecarboxamide
- (3S,4S)-3-({4-[(2,5-dimethylbenzyl)oxy]benzoyl}amino)-4-[(hydroxyamino)carbonyl]-1-piperidinecarboxylate
- $\frac{(3S,4S)-3-(\{4-[(2,5-dimethylbenzyl)oxy]benzoyl\}amino)-N-hydroxy-4-piperidinecarboxamide}{}$
- $\frac{(cis, cis)-3-Amino-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-(N-hydroxy)cyclohexylcarboxamide}{}$
- (cis,cis)-3-Methylamino-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-(N-hydroxy)cyclohexylcarboxamide
- $\label{eq:cis,cis} $$\frac{(cis,cis)-3-Dimethylmino-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(N-hydroxy)cyclohexylcarboxamide$
- $\frac{(cis, trans)-3-Amino-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-1-(N-hydroxy)cyclohexylcarboxamide}{(N-hydroxy)cyclohexylcarboxamide}$

DOCKET NO.: PH-7121-DIV1

- (cis,trans)-3-Dimethylmino-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-(N-hydroxy)cyclohexylcarboxamide
- (cis,trans)-3-(1-Methyl-1-ethylmino)-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-(N-hydroxy)eyclohexylcarboxamide
- (cis,trans)-3-Methylamino-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-(N-hydroxy)cyclohexylcarboxamide
- $\label{lem:cis,cis} $$ $$ (cis,cis)-3-Hydroxy-2-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]carbonyl]amino]-(N-hydroxy)cyclohexylcarboxamide$
- $\label{eq:N-cis-2-[(Hydroxyamino)carbonyl]cyclopentyl} $$A-{(2-methyl-4-quinolinyl)methyl]amino}$ benzamide$
- N-{cis-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-{methyl[(2-methyl-4-quinolinyl)methyl]amino}benzamide
- *N-{cis-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-(3-phenyl-4,5-dihydro-5-isoxazolyl)benzamide*
- *N-{cis-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-[3-(4-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzamide*
- *N-{cis-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-[3-(3-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzamide*

DOCKET NO.: PH-7121-DIV1

- $N-\{cis-2-[(Hydroxyamino)carbonyl]cyclopentyl\}-4-[3-(2-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzamide$
- $N-\{cis-2-[(Hydroxyamino)carbonyl]cyclopentyl\}-4-[3-(4-quinolinyl)-4,5-dihydro-5-isoxazolyl]benzamide$
- 4-[3-(2,6-Dimethyl-4-pyridinyl)-4,5-dihydro-5-isoxazolyl]-N-{cis-2-[(hydroxyamino)carbonyl]cyclopentyl}benzamide
- $N-\{cis-2-[(Hydroxyamino)carbonyl]cyclopentyl\}-3-methoxy-4-[3-(4-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzamide$
- 3-Hydroxy-N-{cis-2-[(hydroxyamino)carbonyl]cyclopentyl}-4-[3-(4-pyridinyl)-4,5-dihydro-5-isoxazolyl]benzamide
- *N-{cis-2-[(Hydroxyamino)carbonyl]cyclopentyl}-4-[5-(2-pyridinyl)-4,5-dihydro-3-isoxazolyl]benzamide*
- $N-\{cis-2-[(Hydroxyamino)carbonyl]cyclopentyl\}-4-[5-(4-pyridinyl)-4,5-dihydro-3-isoxazolyl]benzamide$
- $N-\{4-[(hydroxyamino)carbonyl]-3-pyrrolidinyl\}-1-[(2-methyl-4-quinolinyl)methyl]-1H-indole-5-carboxamide$
- N-{2-[(hydroxyamino)carbonyl]cyclopentyl}-1-[(2-methyl-4-quinolinyl)methyl]-1H-indole-5-carboxamide
- *N*-hydroxy-3-({6-[(2-methyl-4-quinolinyl)methoxy]-1-naphthoyl}amino)-4-piperidinecarboxamide

DOCKET NO.: PH-7121-DIV1

- $N-\{2-[(hydroxyamino)carbonyl]cyclopentyl\}-6-[(2-methyl-4-quinolinyl)methoxy]-1-naphthamide$
- $N-\{2-[(hydroxyamino)carbonyl]cyclopentyl\}-6-[(2-methyl-4-quinolinyl)methoxy]-2-naphthamide$
- $N-\{2-[(hydroxyamino)carbonyl]cyclopentyl\}-6-[(2-methyl-4-quinolinyl)methoxy]-1,2,3,4-tetrahydro-1-isoquinolinecarboxamide$
- $N-\{2-[(hydroxyamino)carbonyl]cyclopentyl\}-1-[(2-methyl-4-quinolinyl)methyl]-1H-benzimidazole-5-carboxamide$
- $N-\{2-[(hydroxyamino)carbonyl]cyclopentyl\}-1-[(2-methyl-4-quinolinyl)methyl]-1H-indole-4-carboxamide$
- (±)-cis-N-hydroxy-2-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1eycloheptanecarboxamide
- $\label{eq:continuity} $$ $$ $$ \frac{\pm -rans-N-hydroxy-2-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-1-eycloheptanecarboxamide $$$
- (4S,5R)-N-hydroxy-5- $(\{4-[(2-methyl-4-quinolinyl)methoxy]benzoyl\}amino)-2-oxohexahydro-1<math>H$ -azepine-4-carboxamide
- $\frac{(3S,4S)-N-\text{hydroxy-3-}(\{4-[(2-\text{methyl-4-quinolinyl})\text{methoxy}]\text{benzoyl}\}\text{amino})-7-}{\text{oxohexahydro-}1H-\text{azepine-4-carboxamide}}$

DOCKET NO.: PH-7121-DIV1

USSN: 10/779,539

 $\frac{(3S,4R)-N-\text{hydroxy-4-}(\{4-[(2-\text{methyl-4-quinolinyl})\text{methoxy}]\text{benzoyl}\}\text{amino})-7-}{\text{oxohexahydro-}1H-\text{azepine-}3-\text{carboxamide}}$

 $\frac{(4S,5R)-N-hydroxy-5-(\{4-[(2-methyl-4-quinolinyl)methoxy]benzoyl\}amino)-7-oxohexahydro-1H-azepine-4-carboxamide}{(4S,5R)-N-hydroxy-5-(\{4-[(2-methyl-4-quinolinyl)methoxy]benzoyl\}amino)-7-oxohexahydro-1H-azepine-4-carboxamide}{(4S,5R)-N-hydroxy-5-(\{4-[(2-methyl-4-quinolinyl)methoxy]benzoyl\}amino)-7-oxohexahydro-1H-azepine-4-carboxamide}{(4S,5R)-N-hydroxy-5-(\{4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino)-7-oxohexahydro-1H-azepine-4-carboxamide}{(4S,5R)-N-hydroxy-5-(\{4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino)-7-oxohexahydro-1H-azepine-4-carboxamide}{(4S,5R)-N-hydroxy-5-(\{4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino)-7-oxohexahydro-1H-azepine-4-carboxamide}{(4S,5R)-N-hydroxy-5-(\{4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino)-7-oxohexahydro-1H-azepine-4-carboxamide}{(4S,5R)-N-hydroxy-5-(\{4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino)-7-oxohexahydro-1H-azepine-4-carboxamide}{(4S,5R)-N-hydroxy-5-(\{4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino)-7-oxohexahydro-1H-azepine-4-carboxamide}{(4S,5R)-N-hydroxy-5-(\{4-[(2-methyl-4-quinolinyl)methoxy-5-(\{4-[(2-methyl-4-(4-[(2-methyl-4-quinolinyl)methoxy-5-(\{4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-methyl-4-[(2-$

 $\frac{(2S,3R)-N-hydroxy-3-(\{4-[(2-methyl-4-quinolinyl)methoxy]benzoyl\}amino)-2-pyrrolidinecarboxamide}{}$

(2R,3R)-N-hydroxy-3- $({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-2-pyrrolidinecarboxamide, and$

tert-butyl (2S,3R)-2-[(hydroxyamino)carbonyl]-3-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-pyrrolidinecarboxylate

or a pharmaceutically acceptable salt form thereof.

- 8. (Original) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to Claim 1 or a pharmaceutically acceptable salt form thereof.
- 9. (Canceled)
- 10. (Withdrawn) A method of treating-according to Claim 9, wherein the <u>a</u> disease or condition is referred to as <u>selected from</u> acute infection, acute phase response, age related macular degeneration, alcoholism, anorexia, asthma, autoimmune disease, autoimmune hepatitis, Bechet's disease, cachexia, calcium pyrophosphate dihydrate

DOCKET NO.: PH-7121-DIV1

USSN: 10/779,539

deposition disease, cardiovascular effects, chronic fatigue syndrome, chronic obstruction pulmonary disease, coagulation, congestive heart failure, corneal ulceration, Crohn's disease, enteropathic arthropathy, Felty's syndrome, fever, fibromyalgia syndrome, fibrotic disease, gingivitis, glucocorticoid withdrawal syndrome, gout, graft versus host disease, hemorrhage, HIV infection, hyperoxic alveolar injury, infectious arthritis, inflammation, intermittent hydrarthrosis, Lyme disease, meningitis, multiple sclerosis, myasthenia gravis, mycobacterial infection, neovascular glaucoma, osteoarthritis, pelvic inflammatory disease, periodontitis, polymyositis/dermatomyositis, post-ischaemic reperfusion injury, post-radiation asthenia, psoriasis, psoriatic arthritis, pydoderma gangrenosum, relapsing polychondritis, Reiter's syndrome, rheumatic fever, and rheumatoid arthritis, sarcoidosis, scleroderma, sepsis syndrome, Still's disease, shock, Sjogren's syndrome, skin inflammatory diseases, solid tumor growth and tumor invasion by secondary metastases, spondylitis, stroke, systemic lupus erythematosus, ulcerative colitis, uveitis, vasculitis, and Wegener's granulomatosis, comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound according to Claim 1.

- 11. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to Claim 2 or a pharmaceutically acceptable salt form thereof.
- 12. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to Claim 3 or a pharmaceutically acceptable salt form thereof.

DOCKET NO.: PH-7121-DIV1 Amendment

USSN: 10/779,539

13. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable

carrier and a therapeutically effective amount of a compound according to Claim 4 or a

pharmaceutically acceptable salt form thereof.

14. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable

carrier and a therapeutically effective amount of a compound according to Claim 5 or a

pharmaceutically acceptable salt form thereof.

15. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable

carrier and a therapeutically effective amount of a compound according to Claim 6 or a

pharmaceutically acceptable salt form thereof.

16. (New) A pharmaceutical composition, comprising: a pharmaceutically acceptable

carrier and a therapeutically effective amount of a compound according to Claim 7 or a

pharmaceutically acceptable salt form thereof.

17. (New) A method of treating a disease or condition selected from Crohn's disease,

psoriasis, psoriatic arthritis, and rheumatoid arthritis, comprising administering to the

mammal in need of such treatment a therapeutically effective amount of a compound

according to Claim 2.

18. (New) A method of treating a disease or condition selected from Crohn's disease,

psoriasis, psoriatic arthritis, and rheumatoid arthritis, comprising administering to the

47

DOCKET NO.: PH-7121-DIV1

USSN: 10/779,539

mammal in need of such treatment a therapeutically effective amount of a compound according to Claim 3.

19. (New) A method of treating a disease or condition selected from Crohn's disease, psoriasis, psoriatic arthritis, and rheumatoid arthritis, comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound according to Claim 4.

20. (New) A method of treating a disease or condition selected from Crohn's disease, psoriasis, psoriatic arthritis, and rheumatoid arthritis, comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound according to Claim 5.

21. (New) A method of treating a disease or condition selected from Crohn's disease, psoriasis, psoriatic arthritis, and rheumatoid arthritis, comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound according to Claim 6.

22. (New) A method of treating a disease or condition selected from Crohn's disease, psoriasis, psoriatic arthritis, and rheumatoid arthritis, comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound according to Claim 7.